Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
March 4 — The Food and Drug Administration's fiscal year 2016 budget request is focused on the agency's essential functions such as biosimilars, food safety and drug compounding, FDA Commissioner Margaret A. Hamburg told a House panel March 4.
The FDA's $4.9 billion FY 2016 request includes $2.7 billion for medical product safety issues, Hamburg testified at a hearing on the budget request before the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies.
The Obama administration's budget proposal, released Feb. 2, seeks $2.7 billion in budget authority and $4.9 billion in total resources for the FDA. The overall FY2016 request is $425 million, or 9 percent, above the FY 2015 levels, according to the proposal. This increase consists of $148 million in budget authority and $277 million in user fees.
“FDA's public health mission is indispensable to the health and well-being of every American,” Hamburg said. “Our budget request plans for efficient spending on essential programs.”
Hamburg, who is stepping down as head of the FDA at the end of March, said the budget request will support the implementation of key provisions of the FDA Safety and Innovation Act of 2012 (FDASIA) and work on combatting antibiotic resistance.
Creating a biosimilars pathway also has been a priority for the agency, Hamburg said. “We expect very soon to be putting out some important guidance and decisions on biosimilar-related issues.”
The FDA also has been “working very hard” to implement the provisions in the Drug Quality and Security Act (DQSA), Hamburg said. The DQSA was enacted by Congress in November 2013 in response to a deadly fungal meningitis outbreak in 2012 that was linked to contaminated sterile compounded drug products.
Hamburg said the agency has issued several draft guidance documents on drug compounding.
Hamburg also said the budget request will support the implementation of the Food Safety and Modernization Act (FSMA). She said the agency plans to issue final FSMA regulations later this year.
Rep. Harold Rogers (R-Ky.), chairman of the full House Appropriations Committee, said he is concerned about the size of the budget request. A $148 million increase “will be tough to swallow,” he said.
Rogers also said he is concerned about the prescription drug abuse epidemic and asked when the FDA would be releasing the final guidance on abuse deterrent formulations of opioids. The draft version of the guidance was issued in January 2013.
Hamburg said the guidance is a “high priority” for the agency.
Rep. Robert Aderholt (R-Ala.), chairman of the subcommittee, said he is concerned about FDA inspections of Chinese facilities.
Hamburg said the agency is making progress on this, but recruiting employees to live in China remains a challenge. Currently the FDA has eight staff members in China with five more pending, she said.
“There are many manufacturers in China that we want to know more about,” she said.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
More information on the hearing is at http://appropriations.house.gov/calendar/eventsingle.aspx?EventID=394021.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)